Be part of the knowledge.™

"Marginal" Donors and "Presumed" Consents

Media Formats

ReachMD Healthcare Image

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details

Presenters

Overview
In this segment, Dr. Millis examines the use of "marginal" or "expanded" donors in the United States, and the various factors behind increasing utilization of these potential donors who would otherwise be ineligible from their own medical problems or comorbidities. The interview then transitions towards some of the ethical issues inherent in "presumed" consent, a hospital policy recently accelerating throughout much of Europe.

Michael Millis, MD

Michael Millis, MD

Maurice Pickard, MD

Maurice Pickard, MD

Recommended

Details

Presenters

Overview
In this segment, Dr. Millis examines the use of "marginal" or "expanded" donors in the United States, and the various factors behind increasing utilization of these potential donors who would otherwise be ineligible from their own medical problems or comorbidities. The interview then transitions towards some of the ethical issues inherent in "presumed" consent, a hospital policy recently accelerating throughout much of Europe.

Michael Millis, MD

Michael Millis, MD

Maurice Pickard, MD

Maurice Pickard, MD

Program Chapters

Segment Chapters

Playlist:

Recommended

Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy

IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue

$IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement$

IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement

IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy

CME/CE Broadcast Replay

Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference

Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies

FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure

First-line Chemotherapy Options in Metastatic PDAC